Clinical Trial Update: Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 extension study of 1.0 mg Letrozole in postmenopausal women with advanced breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Letrozole (letrozole)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Postmenopausal Women With Advanced Breast Cancer | Phase 2 | Status: COMPLETED